Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

cbdMD (YCBD) Cash & Equivalents (2016 - 2025)

cbdMD's Cash & Equivalents history spans 10 years, with the latest figure at $3.4 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 71.96% to $3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 71.96% increase, with the full-year FY2025 number at $2.3 million, down 7.8% from a year prior.
  • Cash & Equivalents hit $3.4 million in Q4 2025 for cbdMD, up from $2.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for YCBD hit a ceiling of $26.4 million in Q3 2021 and a floor of $1.1 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $7.4 million across 5 years, with a median of $2.6 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 78.16% in 2021 and later tumbled 87.11% in 2023.
  • Tracing YCBD's Cash & Equivalents over 5 years: stood at $19.7 million in 2021, then crashed by 82.98% to $3.4 million in 2022, then crashed by 55.11% to $1.5 million in 2023, then surged by 30.92% to $2.0 million in 2024, then surged by 71.96% to $3.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for YCBD at $3.4 million in Q4 2025, $2.3 million in Q3 2025, and $1.1 million in Q2 2025.